A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Multiple Myeloma
DRUG: BMS-986393|DRUG: Alnuctamab|DRUG: Mezigdomide|DRUG: Iberdomide
Incidence of adverse events (AEs), Up to 2 years|Incidence of serious adverse events (SAEs), Up to 2 years|Incidence of adverse events of special interest (AESI), Up to 2 years|Incidence of AEs leading to discontinuation, Up to 2 years|Number of Deaths, Up to 2 years|Establish recommended Phase 2 dose (RP2D), Up to 2 years
Overall response rate (ORR), Up to 2 years|Complete response rate (CRR), Up to 2 years|Very good partial response rate (VGPRR), Up to 2 years|Maximum observed concentration (Cmax), Up to 2 years|Time of maximum observed concentration (tmax), Up to 2 years|Area under the concentration-time curve from time 0 to 28 days [AUC (0-28D)], Up to 2 years
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).